Joan D Beckman
Overview
Explore the profile of Joan D Beckman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beckman J, Zhang P, Nguyen J, Hebbel R, Vercellotti G, Belcher J
Front Immunol
. 2025 Jan;
15():1493904.
PMID: 39776915
Sickle cell disease (SCD) is a devastating hemolytic disease, marked by recurring bouts of painful vaso-occlusion, leading to tissue damage from ischemia/reperfusion pathophysiology. Central to this process are oxidative stress,...
2.
Ivy Z, Belcher J, Khasabova I, Chen C, Juliette J, Abdulla F, et al.
Blood
. 2023 Sep;
142(22):1918-1927.
PMID: 37774369
Vaso-occlusive pain episodes (VOE) cause severe pain in patients with sickle cell disease (SCD). Vaso-occlusive events promote ischemia/reperfusion pathobiology that activates complement. We hypothesized that complement activation is linked to...
3.
Beckman J, Sparkenbaugh E
Curr Opin Hematol
. 2023 Jul;
30(5):153-158.
PMID: 37462409
Purpose Of Review: This review provides an update on recent advances in mechanistic studies of thromboinflammatory mechanisms that contribute to the disease pathology in sickle cell disease (SCD). There is...
4.
Beckman J, DaSilva A, Aronovich E, Nguyen A, Nguyen J, Hargis G, et al.
J Thromb Haemost
. 2023 Feb;
21(5):1366-1380.
PMID: 36738826
Background: Vascular activation is characterized by increased proinflammatory, pro thrombotic, and proadhesive signaling. Several chronic and acute conditions, including Bcr-abl-negative myeloproliferative neoplasms (MPNs), graft-vs-host disease, and COVID-19 have been noted...
5.
Tremblay D, Winters A, Beckman J, Naymagon L, Patel R, Mascarenhas J, et al.
Thromb Res
. 2022 Aug;
218:8-16.
PMID: 35963121
Splanchnic vein thrombosis (SVT) in the setting of myeloproliferative neoplasm (MPN) is a unique clinical entity that requires close interdisciplinary coordination for proper diagnosis and management. The pathobiology of MPN-SVT...
6.
Campbell A, Seelig D, Beckman J, Minor K, Heinrich D, Friedenberg S, et al.
J Vet Intern Med
. 2022 Jul;
36(4):1237-1247.
PMID: 35815881
Background: Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL. Objectives: To determine the prevalence...
7.
Azul M, Vital E, Lam W, Wood D, Beckman J
Transl Res
. 2022 Mar;
246:1-14.
PMID: 35354090
Sickle cell disease (SCD) is caused by a single point mutation in the β-globin gene of hemoglobin, which produces an altered sickle hemoglobin (HbS). The ability of HbS to polymerize...
8.
Reeves B, Beckman J
Curr Hematol Malig Rep
. 2021 Apr;
16(3):304-313.
PMID: 33876389
Purpose Of Review: Thrombosis remains a leading cause of morbidity and mortality in BCR/ABL negative myeloproliferative neoplasms (MPN). Circulating blood cells are both increased in quantity and qualitatively abnormal in...
9.
Zhang P, Nguyen J, Abdulla F, Nelson A, Beckman J, Vercellotti G, et al.
Front Immunol
. 2021 Apr;
12:632709.
PMID: 33841413
Recent evidence indicates that hemolysis in sickle cell disease (SCD) promotes inflammation innate immune signaling through toll-like receptor 4 (TLR4). Free heme released by hemolyzed red blood cells can bind...
10.
Beckman J, Abdullah F, Chen C, Kirchner R, Rivera-Rodriguez D, Kiser Z, et al.
Front Immunol
. 2021 Feb;
11:613278.
PMID: 33542720
Heme, released from red blood cells in sickle cell disease (SCD), interacts with toll-like receptor 4 (TLR4) to activate NF-κB leading to the production of cytokines and adhesion molecules which...